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Abstract
Background—Evidence from animal and cell line experimental studies support a beneficial role 
for vitamin D in prostate cancer (PCa). While the results from human studies have been mainly 
null for overall PCa risk, there may be a benefit for survival. We assessed the associations of 
circulating 25-hydroxyvitamin D [25(OH)D] and common variation in key vitamin D-related 
genes with fatal PCa.
Methods—In a large cohort consortium, we identified 518 fatal cases and 2986 controls with 
25(OH)D data. Genotyping information for 91 single nucleotide polymorphisms (SNPs) in 7 
vitamin D-related genes (VDR, GC, CYP27A1, CYP27B1, CYP24A1, CYP2R1, RXRA) was 
available for 496 fatal cases and 3577 controls. We used unconditional logistic regression to 
calculate odd ratios (OR) and 95% confidence intervals (CI) for the associations of 25(OH)D and 
SNPs with fatal PCa. We also tested for 25(OH)D-SNP interactions among 264 fatal cases and 
1169 controls.
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Results—We observed no statistically significant relationship between 25(OH)D and fatal PCa 
[OR(95% CI)extreme quartiles=0.86(0.65-1.14); p-trend=0.22] or the main effects of the SNPs and 
fatal PCa. There was suggestive evidence that associations of several SNPs (including 5 related to 
circulating 25(OH)D) with fatal PCa were modified by 25(OH)D. Individually these associations 
would not remain significant after considering multiple testing; however the p-value for the set-
based test for CYP2R1 was 0.002.
Conclusions—In our study, we did not observe statistically significant associations for either 
25(OH)D or vitamin D-related SNPs with fatal PCa. Effect modification of 25(OH)D associations 
by biologically plausible genetic variation may deserve further exploration.
Keywords
circulating 25-hydroxyvitamin D; vitamin D genes; fatal prostate cancer; single nucleotide 
polymorphisms; gene-environment interaction
Introduction
In addition to its role in bone health, vitamin D regulates expression of 3-5% of genes, many 
of which are related to cancer1. Evidence from animal and cell line experimental studies 
supports a beneficial role for vitamin D in the prevention and treatment of prostate cancer 
(Pca)2,3, but results from human epidemiologic studies are conflicting. Epidemiologic 
studies focusing on circulating 25(OH)D have not supported a protective association for 
higher 25(OH)D with overall PCa risk4-8. More recently, there has been growing interest in 
whether vitamin D may specifically influence cancer survival and prognosis9. This is 
particularly relevant for PCa because indolent and fatal disease may be etiologically 
different10. However, only a few studies have investigated the relationship between 
circulating 25(OH)D and PCa specific mortality; some found a protective association6,11,12, 
while others have not7,13.
At the same time, an increasing number of studies have explored whether common genetic 
variants among genes that play a role in vitamin D metabolism and signaling are associated 
with PCa risk. Most studies have focused on five specific SNPs in the vitamin D receptor 
gene (VDR), with inconsistent results14. More comprehensive studies assessing common 
variation across the VDR and several other vitamin D pathway genes and PCa risk have 
yielded few additional findings15-18. Furthermore, only two studies have assessed the 
relationship of common variation in these vitamin D pathway genes with the endpoint of 
fatal PCa; while both studies found suggestive associations, their results were not 
consistent6,19. A yet unexplored area is whether associations between vitamin D related 
SNPs and fatal PCa may be modified by circulating levels of 25(OH)D. Identification of 
such interactions would lend mechanistic and causal support for an association of vitamin D 
with PCa.
Recently, the Health Professionals Follow-up Study (HPFS) reported that higher pre-
diagnostic 25(OH)D levels were associated with a 57% statistically significant reduction in 
the risk of fatal PCa (highest vs. lowest quartile)6. Using a pathway-based approach, the 
HPFS also reported that common variation in seven vitamin D-related genes (CYP27A1, 
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CYP2R1, CYP27B1, GC, CYP24A1, RXRA, and VDR) was related to fatal PCa, in particular 
for VDR andCYP27A16. The genes were chosen because of laboratory evidence that they are 
directly involved in vitamin D metabolism and signaling.
The objectives of the current study were to follow-up on the findings from the HPFS within 
a large consortium of prospective cohort studies. Specifically, we 1) assessed whether men 
with low circulating 25(OH)D are at an increased risk of fatal PCa and 2) investigated the 
association of common variation in vitamin D-pathway genes with fatal PCa. Furthermore, 
we also explored gene-environment interactions between circulating 25(OH)D, vitamin D 
pathway SNPs, and fatal PCa.
Material and Methods
Study population
The Breast and PCa Cohort Consortium (BPC3) is a collaboration of well-established 
prospective cohort studies investigating genetic risk factors for breast and PCa and has been 
described in detail previously20. Studies that participated in this analysis included, the 
Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study7, the European 
Prospective Investigation into Cancer and Nutrition Cohort (EPIC)5, the Health 
Professionals Follow-up Study (HPFS)6, the Physicians’ Health Study (PHS)21, and the 
Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial15. The respective 
local Institutional Review Boards approved each study. Each cohort provided a nested series 
of PCa cases and controls; within each cohort controls without a previous diagnosis of 
prostate cancer were matched to cases on factors such as age and ethnicity depending on the 
cohort20. In addition, covariate information including, body mass index (BMI, kg/m2), 
history of diabetes (yes/no), smoking status (never, current, former), and age at blood draw 
and diagnosis were available. We restricted the current study to men who self-reported as 
being of European descent.
Outcome Ascertainment
Men with incident PCa were identified through population-based cancer registries or self-
report confirmed by medical records, including pathology reports. Data on disease stage and 
grade at the time of diagnosis were noted, when available. The primary outcome was fatal 
PCa risk. Cases were followed for overall mortality and PCa specific mortality using a 
combination of death certificates, medical record review, and population registries.
25(OH)D Assessment
Pre-diagnostic circulating 25(OH)D levels were assayed separately in each study and were 
available for 518 fatal PCa cases and 2986 controls. Details of 25(OH)D assessment, 
including type of assay and quality control measures, specific to each cohort has been 
previously published5-7,15,21 (See also Supplementary Table 1). Some studies conducted 
multiple batches of assays at differing time points (e.g. HPFS selected case and controls in 
four separate batches and each batch was assayed at a different time point: blood draw to 
January 1996, February 1996 to January 1998, February 1998 to January 2000, and February 
2000 to January 2004). To account for study, season of blood draw, and laboratory variation 
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due to multiple batches of assays conducted at differing time points within a study, we 
created study-, season- and batch- quartile and median cut points based on levels in the 
control subjects. Seasons were defined as summer (June to August)/autumn (September to 
November) and spring (March to May)/winter (December to February). We did not analyze 
absolute cut points of 25(OH)D because of substantial variation among the different assays.
Genotyping
A subset of the BPC3 cases with aggressive PCa, defined as Gleason 8-10 or stage C/D, and 
controls were included in a Genome Wide Association Study (GWAS) to identify novel risk 
variants for aggressive PCa20. Genotyping was performed for the majority of the subjects 
using the Illumina Human 610-Quad array, but some subjects from the PLCO were 
genotyped on other Illumina arrays (i.e. HumanHap 317K+240K or 550K). Quality control 
measures have been ssdescribed in detail elsewhere20. In brief, samples were excluded if 
genotyping call rate was <95%, or autosomal heterozygosity was <0.25 or >0.35. Additional 
common variants and missing values were imputed using MACH and the Phase II CEU 
HapMap data22. We were able to extract genotypes or a proxy (R2>=0.8) for 88 of the 95 
SNPs included in the original study. Four of the SNPs were unavailable including the VDR 
SNPs rs2228570 (Fok1), rs11168275, rs11574032, and RXRA SNP rs34312136 and three 
were partially tagged (0.6<R2<0.8), rs10875693 (VDR), rs7853934, rs41400444 (RXRA). Of 
the men with GWAS data there were 264 fatal PCa cases and 1169 controls who also had 
overlapping information on circulating 25(OH)D.
Statistical Methods
All statistical tests were two-sided and were conducted using SAS v9.3 (SAS Institute, Cary, 
NC) and R (http://www.r-project.org/) statistical packages. We used logistic regression to 
calculate the odds ratios (OR) and 95% confidence intervals (CI) for the associations of 
circulating 25(OH)D and vitamin D pathway-SNPS with risk of incident fatal PCa compared 
to controls. The primary models used data pooled across all 5 cohorts and were adjusted for 
age at diagnosis (cases) or selection (controls) and cohort.
For 25(OH)D, we also created models adjusting for year of blood draw, time from blood 
draw to diagnosis, BMI (kg/m2), diabetes history (y/n), and smoking (never, current, 
former). The lowest quartile of 25(OH)D was used as the reference category and tests for 
trend used an ordinal variable (values of 1-4) corresponding to the quartile in which the 
individual's circulating 25(OH)D fell. We conducted a sensitivity analysis excluding men 
who were diagnosed with PCa within 2 years after blood draw. For the SNP analyses, we 
used an allele-dosage model. Finally, we conducted exploratory analyses to test for 
SNP-25(OH)D interactions in relation to fatal PCa risk among the subset of men with both 
circulating 25(OH)D and genetic data. We performed stratified analysis for the association 
of the SNPs with fatal PCa in those men with high vs. low 25(OH)D (dichotomized at the 
median). We tested for multiplicative interaction by adding a cross-product term to the 
model (SNP*25(OH)D) and assessed significance with the Wald test. To improve power of 
the statistical test for interaction, we used a continuous measure of 25(OH)D that was 
standardized for season, cohort and batch using the method described by Rosner et al.23. 
Briefly, in this method, beta coefficients from a linear regression model of 25(OH)D with 
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batch, season and cohort indicators were averaged; for each specific cohort-season-batch 
combination, the difference between the corresponding beta coefficient from the model and 
the average coefficient was subtracted from the unadjusted 25(OH)D value to create a 
continuous measurement that was standardized to the average cohort-season-batch.
We implemented set-based tests across the entire pathway of 7 genes and at the individual 
gene level for the association with fatal PCa and for SNP-25(OH)D interactions. Set-based 
test may have enhanced power due to aggregating multiple signals within a set, leveraging 
the correlation between SNPs, and reducing the multiple testing burden. The mathematical 
details of the logistic regression kernel machine models and gene-environment set-based 
association test (GESAT) is described elsewhere24-27. In brief, the kernel machine model 
treats each of the included SNPs as a random effect; desired covariates (e.g. age and study) 
are entered as fixed effects. The joint effect of the entire SNP-set is considered and the 
degrees of freedom are calculated with respect to the correlation between the SNPs in the 
set, improving the power of the hypothesis test. The null hypothesis that the variance of the 
SNP random effects is zero (i.e. that the SNPs individually or jointly are not associated with 
disease) can be tested using a score test. Similarly, the GESAT27 considers the coefficients 
of the gene-environment interaction terms as random effects and develops a variance 
component score test within the induced generalized linear mixed model framework.
We report nominal p-values, but we also calculated the effective number of independent 
tests for the individual SNP associations28. After accounting for linkage disequilibrium, the 
91 SNPs corresponded to 77 independent tests; therefore a p-value significance threshold of 
0.0006 controls the experiment-wide type I error rate at the 0.05 level.
Results
Supplementary Tables 2a-c describe characteristics of the fatal PCa cases and controls for 
those with a) circulating 25(OH)D b) genotype data, and c) both circulating 25(OH)D and 
GWAS information. Those participating in the GWAS were more heavily weighted to 
higher stage and grade due to the selection criteria described above.
25(OH)D and fatal PCa
Among the men with pre-diagnostic circulating 25(OH)D, 518 died from PCa over a median 
follow-up time of 8.1 years after diagnosis. The median levels of 25(OH)D in the first and 
fourth quartile respectively were 14.4 ng/mL (35.9 nmol/L) and 33.0 ng/mL (82.4 nmol/L). 
Table 1 shows the ORs and 95% CI's by quartiles of circulating 25(OH)D for risk of fatal 
PCa, adjusted for age at blood draw, time from blood draw to diagnosis and cohort, BMI. 
There was no significant association of 25(OH)D and risk of fatal PCa across the five 
cohorts combined (OR: 0.86; 95% CI: 0.65-1.14 (highest vs. lowest quartile); p-trend=0.22). 
Three of the five cohorts showed an inverse trend, but only one (HPFS) was statistically 
significant (Supplementary Table 3). When we excluded HPFS, the pooled results 
remained non-significant (ORhighest vs. lowest quartile: 0.96; 95% CI: 0.70, 1.31; p-trend=0.73) 
(data not shown). There was no evidence for heterogeneity between studies when we looked 
at the estimates for the highest vs. lowest quartiles using the Cochran's Q test. Additional 
adjustment for diabetes status and smoking did not change the results.
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Vitamin D pathway common genetic variation and fatal PCa
Among the men with available genotype information, 496 died of PCa. Figure 1 shows the 
p-value for the per-allele associations of each SNP and fatal PCa and Supplementary Table 
4 provides the OR and 95% CI for each SNP. None of the SNPs were significantly 
associated with fatal PCa and the global p-value across the pathway from the kernel machine 
test was not significant (p=0.44).
SNP-25(OH)D interactions and fatal PCa
In the subset of men who had both circulating 25(OH)D and genotype data, there were 264 
PCa deaths. Table 2 details the SNPs that were either nominally significant in strata of high 
vitamin D (n=6) or low vitamin D (n=11) or had a p-interaction<0.05 (n=9); none of the 
SNPs remained statistically significant after considering multiple testing so these 
associations may be due to chance. However, the results of the GESAT test across the entire 
pathway was p=0.06 and at the gene-level CYP2R1 was statistically significant (p=0.002). 
Supplementary Table 5 includes the results for all of the SNPs and the GESAT tests. We 
also assessed whether the vitamin D pathway SNPs were associated with circulating 
25(OH)D levels. Our results replicated SNPs in the genes GC and CYP2R1 known to be 
related to circulating 25(OH)D from previous GWAS15 (Supplementary Table 6). Five of 
these SNPs (GC: rs1155563 and CYP2R1: rs2060793, rs12794714, rs1562902, and 
rs11023374) were among the SNPs whose association with fatal PCa differed by circulating 
25(OH)D level (Table 2).
Discussion
In our large cohort consortium we did not find evidence to support associations of 
circulating 25(OH)D or common variation in key vitamin D pathway genes with risk of fatal 
PCa. In our exploratory analysis for SNP-25(OH)D interactions, several nominally 
significant associations between vitamin D pathway SNPs and fatal PCa were observed in 
the stratified analysis at either high or low circulating 25(OH)D levels and a gene-level 
significant association was observed for CYP2R1.
The pooled association across all 5 cohorts between higher circulating 25(OH)D and risk of 
fatal PCa was in the protective direction, but was not statistically significant. Three of the 
five cohorts showed an inverse trend, but only HPFS (as published previously6) was 
statistically significant. Other studies have published findings on circulating 25(OH)D and 
fatal PCa7,12,13. The ATBC study (294 fatal PCa cases) did not find a statistically significant 
association between prospectively collected circulating 25(OH)D and fatal PCa7. Two 
studies assessed the association of progression to PCa specific mortality and 25(OH)D in 
post-diagnostic blood. A population-based study performed in 1476 men with PCa in the 
metropolitan Seattle-Puget Sound area found no significant association for progression to 
PCa specific mortality13, while a different study based in 160 Norwegian men observed a 
statistically significant 67% decreased risk of progression with medium to high 25(OH)D 
levels compared to low levels (<50nmol/L), especially in men receiving hormone therapy12. 
A study combining data from the HPFS and the PHS also found a protective association 
between pre-diagnostic circulating 25(OH)D and PCa mortality among cases, but the 
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association mostly driven by the HPFS11. A few studies have generated concern that there 
may be an increased risk of aggressive PCa with higher circulating 25(OH)D15,29; our study 
does not support an increased risk of fatal PCa at higher circulating 25(OH)D.
Varying results by cohort could be due to differences in screening practices, severity of 
disease at diagnosis, prevalence of factors that could modify the association, or chance. 
PLCO and HPFS were both highly screened populations and showed the strongest protective 
associations for vitamin D with fatal PCa. It is difficult to explain this observation, but one 
potential hypothesis is that vitamin D maybe more effective in preventing progression in 
PSA screened populations where disease is treated early; cancers detected at a later point in 
the natural history of the disease could be more likely to be resistant to this vitamin D effect. 
There were no major differences in the range of vitamin D levels in each cohort; in 
particular the median levels in the first and fourth quartiles in the controls were comparable 
among the cohorts (Supplementary Table 3). Overall, the difference between the medians 
of the first and fourth quartiles of 25(OH)D in the controls was 18.6 ng/mL (46.5 nmol/L) 
with more than a quarter of the men classified as at risk for having inadequate vitamin D 
levels (<20ng/mL or <50 nmol/L) (Table 2). While a single measurement of circulating 
25(OH)D has been shown to have reasonable validity over time30, multiple measurements 
would more accurately reflect long-term exposure. Additionally, the 25(OH)D assays 
differed across cohort and were not calibrated to a common assay nor standardized to an 
accepted gold standard, preventing the use of absolute cut points for comparisons.
We did not observe evidence for confounding by BMI, diabetes or smoking, but we did not 
have information on other potential confounders such as physical activity. For example, if 
higher levels of physical activity is associated with higher circulating 25(OH)D6 and lower 
risk for PCa mortality the observed results could be biased away from the null.
We did not observe any statistically significant main effects of common variation in key 
vitamin D pathway-related genes on risk fatal PCa. We did not replicate the findings in the 
prior HPFS study6 or the findings from a case-only study that assessed 48 tag-SNPs in VDR, 
CYP27B1, and CYP24A1 and progression to PCa mortality19.
To our knowledge this is the first study to assess interactions between a comprehensive set 
of SNPs in key genes related to vitamin D signaling and metabolism and levels of 
circulating 25(OH)D in relation to fatal PCa. The overall GESAT pathway p-value=0.06 and 
suggestive effect modification by circulating 25(OH)D on the association of a number of 
SNPs and fatal PCa was observed. Several of these SNPs were located in GC (the vitamin D 
binding protein) and CYP2R1 (a 25-hydroxylase)—genes which have been observed to 
influence circulating 25(OH)D levels31. The strongest evidence for effect modification was 
in the CYP2R1 gene; 5 SNPs had nominally significant p-interaction and the gene level 
GESAT was statistically significant (p-value=0.002). Interestingly, four of these five 
CYP2R1 SNPS were associated with levels of circulating 25(OH)D in our study. On 
average, men who carried an allele that was associated with higher circulating 25(OH)D in 
the general population, but who still had low circulating 25(OH)D levels were at higher risk 
for fatal PCa. The other SNPs were mainly located in CYP24A1, an enzyme critical for the 
catabolism of vitamin D, and VDR, the key nuclear receptor that mediates the genomic 
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effects of vitamin D. Overexpression of CYP24A1 has been shown to correlate with worse 
outcomes in several solid tumors, including prostate32. Conversely, higher VDR expression 
has been associated with better PCa survival33. Given the strong biological plausibility that 
circulating 25(OH)D may affect the association of these SNPs with fatal PCa, future study is 
warranted.
A few studies have assessed circulating 25(OH)D-SNP interactions for overall PCa 
incidence. Most of these studies were small candidate gene studies that focused mainly on 
VDR polymorphisms including Bsm1 (rs1544410)15,34,35, Cdx2 (rs11568820)15,35, and 
Fok1 (rs2228570/rs10735810)15,21,35-37 and the results have been inconclusive. Our study 
was unable to assess Fok1 and we did not observe any gene-environment interactions with 
Cdx2 or Bsm1. Recently, a study of 1514 participants found that a variant in VDR 
(rs7968585) modified the association of 25(OH)D and a composite clinical outcome 
(incident hip fracture, myocardial infarction, cancer incidence, and total mortality). This 
finding was further replicated through a meta-analysis of 3 independent cohorts38. Although 
not statistically significant, our data were consistent with this finding. Rs7967152 (r2=0.87 
with rs7968585) showed a stronger association with fatal PCa in men with low 25(OH)D: 
OR(95% CI)low 25(OH)D: 1.30 (0.97-1.74), p=0.08 compared to those with high 25(OH)D: 
OR(95% CI)high 25(OH)D: 0.89(0.66-1.20), p=0.46 (Supplementary Table 6).
The relationship between circulating 25(OH)D and the prostate environment is complex and 
could be mediated by expression of several vitamin-D related genes. It is possible that 
circulating levels of 25(OH)D do not adequately reflect the bioavailability in the prostate 
tissue as CYP27B1 is expressed in the prostate and can synthesize 1,25(OH)2D from 
25(OH)D within the prostate. Nonetheless, a clinical trial of vitamin D supplementation 
indicated that levels of vitamin D metabolites (25(OH)D and 1,25(OH)2D) in prostate tissue 
correlated positively with serum circulating levels39. The influence of 25(OH)D in the 
prostate environment may be further mediated by expression of VDR or CYP24A1 in 
prostate tissue. Higher expression of VDR in prostate tumor tissue has been associated with a 
decreased risk of PCa progression33 and increased expression of CYP24A1 was observed to 
be associated with advanced stage PCa and resistance to vitamin D-based therapies32. 
Studies integrating circulating 25(OH)D with tumor molecular profiling could shed light on 
the inconsistent results to date.
A major strength of this study was the combination of several large cohort studies with 
prospective blood collection and relatively long-term and complete follow-up, allowing for 
the assessment of fatal PCa, an endpoint that has been traditionally difficult to study 
epidemiologically with substantial numbers of outcomes due to the long natural history of 
the disease. With a median follow-up of 8.1 years, we were able to capture 518 fatal prostate 
cancer cases. Even so, longer follow-up would allow for greater accrual of deaths further out 
in the natural history of the disease. Finally, after subsetting the men who had both levels of 
circulating 25(OH)D and genotyping data, our sample size was reduced, limiting our power 
to detect interactions.
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Conclusions
We did not find strong evidence to support the hypothesis that circulating 25(OH)D or 
common variation in key vitamin D pathway genes is related to a decreased risk of fatal 
PCa. We observed suggestive modification of the association between some of the SNPs and 
fatal PCa by circulating 25(OH)D levels, especially in CYP2R1. These latter findings could 
be further assessed in other cohort studies or in clinical trials of vitamin D supplementation 
or vitamin D agonists.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Condensed Abstract: Given the high prevalence of prostate cancer (PCa) and the wide 
international variation in vitamin D status, identifying causal links between the two could 
have a large public health impact. Few studies have addressed risk of fatal PCa. In this 
study, we did not observe a convincing association of circulating 25(OH)D or SNPs in 
key vitamin D-related genes with fatal PCa. However, interactions between biologically 
relevant SNPs and circulating 25(OH)D with respect to fatal PCa may deserve further 
investigation.
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Figure 1. 
Manhattan plot showing p-values for the association of each individual vitamin D SNP and 
fatal prostate cancer risk. Each SNP is color coded by gene and represented by a circle on 
the plot.
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